Mesalazine formulations are essential for treating ulcerative colitis (UC), and intolerance to these formulations complicates the treatment of this condition. Some cases of mesalazine formulation intolerance are caused by the excipients rather than the active ingredient mesalazine. Therefore, mesalazine administration can be continued in such cases by changing the mesalazine formulation. This report describes a case of intolerance to mesalazine in which UC was effectively treated by switching mesalazine formulations. A drug-induced lymphocyte stimulation test suggested that allergy to the additive povidone was the cause of mesalazine formulation intolerance. This is the first case study to identify an additive that caused mesalazine formulation intolerance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12328-020-01216-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function.
Neurogastroenterol Motil
January 2025
Sir Peter Mansfield Imaging Centre, School of Physics and Astronomy, University of Nottingham, Nottingham, UK.
Background: The human colon receives 2 L of fluid daily. Small changes in the efficacy of absorption can lead to altered stool consistency with diarrhea or constipation. Drugs and formulations can also alter colonic water, which can be assessed using the magnetic resonance imaging (MRI) longitudinal relaxation time constant, T1.
View Article and Find Full Text PDFComparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis.
Clin Ther
January 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:
Purpose: Mesalazine and thiopurines are important therapeutic agents for pediatric patients with ulcerative colitis (UC). Mesalazine, which may be administered in different forms depending on delivery mechanisms, can affect thiopurine metabolism, leading to increased 6-thioguanine nucleotides (6-TGN) levels. Therefore, when using these two drugs simultaneously, their interactions must be considered.
View Article and Find Full Text PDFPhysiologically Based Biopharmaceutics Modeling Coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: A Tough Nut to Crack.
AAPS PharmSciTech
December 2024
Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, 500090, Telangana, India.
Mesalamine is a locally acting anti-inflammatory drug used to treat mild to moderate ulcerative colitis. Because of complex formulation principle and high in vivo variability, development of bioequivalent formulation for mesalamine is challenging. Further, fed state possess significant challenges for bioequivalence (BE) due to interplay of multiple factors.
View Article and Find Full Text PDFDevelopment of mesalamine loaded-fenugreek gum decorated pectin microspheres for colonic drug delivery: Ex-vivo and in-vitro characterizations.
Ann Pharm Fr
November 2024
Department of Pharmaceutics, KVPS's, Institute of Pharmaceutical Education, 425428 Boradi, Maharashtra, India. Electronic address:
Mesalamine (MES) is a preferred therapeutic agent for managing various colon disorders, including inflammatory bowel diseases (IBD). However, conventional oral dosage forms of MES face significant limitations, which reduce their effectiveness in managing these conditions. To overcome these challenges, advanced dosage forms of MES are essential.
View Article and Find Full Text PDFRectal 5-aminosalicylic acid induced pancreatitis in a patient with newly diagnosed ulcerative colitis.
Clin J Gastroenterol
November 2024
Department of Gastroenterology, University Hospital Geelong, Barwon Health, 272 Ryrie Street Geelong, Geelong, Victoria, 3220, Australia.
Oral 5-aminosalicylic acid (5-ASA) are well recognised to have the potential to cause drug-induced acute pancreatitis; however, there have only been infrequent case reports of rectal formulations causing acute pancreatitis. We describe a case of rectal Mesalazine (a 5-ASA) induced acute pancreatitis. The patient was commenced on rectal 5-ASA therapy 8 weeks prior to presentation following a diagnosis of Montreal classification E1 Ulcerative Colitis on colonoscopy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!